Loading…
Loading…
EQUITY / NASDAQ · XNCM
bioAffinity Technologies, Inc.
01 / RESEARCH
8 financial reports are available for research.
Start research ↗6.53 USD · -0.4573%
Observed: Oct 1, 2026, 10:41 AM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
09/30/2026 · 6.56 USD · Volume 107,478
680 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | Prior year | Change |
|---|---|---|---|
| Cash and cash equivalents | 2,429,719 USD | — | — |
| Net income | -3,366,082 USD | — | — |
| Operating profit | -3,334,864 USD | — | — |
| Revenue | 1,510,579 USD | — | — |
| Total assets | 7,619,279 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 1ConsolidatedUnits · USD | 2025 / Quarter 2ConsolidatedUnits · USD | 2025 / Year endConsolidatedUnits · USD | 2025 / Quarter 3ConsolidatedUnits · USD | 2025 / Quarter 3ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 2,429,719 USD | — | — | 3,098,366 USD | 6,449,782 USD | 6,449,782 USD | 7,669,195 USD | — |
| Net incomeIncome statement | -3,366,082 USD | -6,996,692 USD | — | -3,630,610 USD | — | -14,909,754 USD | -5,051,084 USD | -11,772,288 USD |
| Operating profitIncome statement | -3,334,864 USD | -6,951,840 USD | — | -3,616,976 USD | — | -10,572,508 USD | -2,292,846 USD | -7,435,545 USD |
| RevenueIncome statement | 1,510,579 USD | 2,862,106 USD | — | 1,351,527 USD | — | 6,161,959 USD | 1,446,066 USD | 4,569,146 USD |
| Total assetsBalance sheet | 7,619,279 USD | — | — | 7,945,252 USD | 10,960,772 USD | 10,960,772 USD | 11,546,369 USD | — |
| Total equityBalance sheet | 3,768,797 USD | — | 3,647,072 USD | 3,661,386 USD | 7,277,656 USD | 7,277,656 USD | 8,902,198 USD | — |
| Total liabilitiesBalance sheet | 3,850,482 USD | — | — | 4,283,866 USD | 3,683,116 USD | 3,683,116 USD | 2,644,171 USD | — |
| Capital expendituresCash flow statement | — | 95,633 USD | — | 5,663 USD | — | 60,568 USD | — | 60,567 USD |
| Financing cash flowCash flow statement | — | 2,503,914 USD | — | -118,513 USD | — | 14,733,901 USD | — | 13,393,750 USD |
| Investing cash flowCash flow statement | — | -95,633 USD | — | -5,663 USD | — | -60,568 USD | — | -60,567 USD |
| Operating cash flowCash flow statement | — | -6,428,344 USD | — | -3,227,240 USD | — | -9,328,842 USD | — | -6,769,279 USD |
| Report source | Open report ↗ Published: 08/07/2026 | Open report ↗ Published: 08/07/2026 | Open report ↗ Published: 08/07/2026 | Open report ↗ Published: 05/11/2026 | Open report ↗ Published: 08/07/2026 | Open report ↗ Published: 03/16/2026 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 11/14/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.